[Acetylation phenotype in Graves' disease].
Acetylation phenotype was determined with sulfamidine technique in 25 patients with Graves-Basedow disease including 19 female and 6 male patients aged between 21 and 64 years. The control group consisted of 23 healthy volunteers (8 female and 15 male individuals aged between 28 and 57 years) from the Szczecin province . Acetylation phenotype was determined before and after therapy with thiamazole++. Prevalence of fast acetylators was noted in the patients with Graves-Basedow disease in comparison with healthy population. The administered treatment decreased the percentage of fast acetylators. Fast acetylators responded to the treatment earlier achieving clinical euthyreosis.
Górnik
W
W
Syrenicz
A
A
Gawrońska-Szklarz
B
B
Wójcicki
J
J
D000107:Acetylation; D000328:Adult; D001711:Biotransformation / Q000502:physiology; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008297:Male; D008713:Methimazole / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008875:Middle Aged; D010641:Phenotype; D013418:Sulfamethazine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
D013418:Sulfamethazine; D008713:Methimazole
Fenotyp acetylacji w chorobie Gravesa-Basedowa.